NLS Pharmaceutics Ltd NLSP 深 滬
已收盤 10-30 16:00:00 美东时间
0.762
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.762
- 總市值 373.99万
- 52周最高 41.50
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 7.40
- 委 比 0.00%
- 總股本 490.80万
- 歷史最高 2940.00
- 量 比 0
- 振 幅 0.00%
- 歷史最低 7.40
- 每 手 1
- 風險率 3.89%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多NewcelX AG Releases Updated Corporate Presentation
NewcelX AG Releases Updated Corporate Presentation NewcelX AG has released an updated corporate presentation ahead of key spring 2026 investor and partnering conferences, highlighting its strategic focus on Type 1 Diabetes cell therapy and recent additions to its Scientific Advisory Board and leader
01-29 20:02
NewCelX Appoints EY as New Auditor Following Merger
NewcelX ( ($NCEL) ) has issued an update. NewCelX Ltd., previously known as NLS...
2025-11-21 05:57
NewcelX CEO Issues Letter to Shareholders
ZURICH, Nov. 4, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL), a Swiss clinical-stage biopharmaceutical company developing cell-based and small-molecule therapies for neurodegenerative an...
2025-11-04 20:00
NewcelX Unveils Strategic Roadmap Post-Merger with NLS Pharmaceutics
NewcelX ( ($NCEL) ) has provided an announcement. On November 3, 2025, NewcelX ...
2025-11-03 22:20
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger
Combined Company Re-Named NewcelX Ltd., to Commence Trading on the Nasdaq Capital Market on October 31, 2025 under the Ticker Symbol "NCEL" ZURICH and NESS ZIONA, Israel , Oct. 30, 2025 /PRN...
2025-10-31 04:15
NLS Pharma And Aexon Labs Expand DOXA Platform With AEX-6xx Series, New Generation Of Small Molecules Targeting Arousal Stability, Cognition, And Neuroprotection
DOXA Platform Expansion Strengthens Cognitive, Arousal, and Neuroprotective ProgramsSupported by Solid Cash Position and Strategic Funding OutlookZURICH, Oct. 30, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd.
2025-10-30 19:15
NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs
DOXA Platform Expansion Strengthens Cognitive, Arousal, and Neuroprotective Programs Supported by Solid Cash Position and Strategic Funding Outlook ZURICH, Oct. 30, 2025 /PRNewswire/ -- NLS ...
2025-10-30 19:00
NLS Pharmaceutics to execute 1-for-10 reverse share split
Swiss drugmaker NLS Pharmaceutics (NASDAQ:NLSP) plans to implement a reverse share split of its issued and outstanding common shares, par value CHF 0.03 per share, at a ratio of 1-for-10. The shares a...
2025-10-29 18:22
NLS Pharmaceutics, Kadimastem Receive Approval To List Common Shares On Nasdaq After Merger Under NewcelX Name, NCEL Ticker
NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system ("CNS") disorders, and Kadimastem Ltd. (TASE:
2025-10-23 18:04
NLS Pharmaceutics Shareholders Approve Merger with Kadimastem
An update from NLS Pharmaceutics ( ($NLSP) ) is now available. On September 30,...
2025-09-30 19:48
